The NHS Long Term Plan committed to accelerate the uptake of selected innovative medical devices, diagnostics and digital products to patients faster, by developing the MedTech Funding Mandate (MTFM) policy, which is delivered in partnership with Health Innovation Networks. Launched in April 2021, we are currently supporting two products in 2024:
- APOS from APOS Health- a non-invasive device worn on the feet to reduce pain and improve function in patients with knee osteoarthritis.
- Spectra Optia from Terumo- automated red blood cell exchange and service development for patients with sickle cell disease.
Previous MTFM initiatives include:
- Placental growth factor based testing (PlGF) to rule out pre-eclampsia – successfully introduced into standard clinical practice in line with NICE guidance in the vast majority of maternity units in England within four years of the first evaluation in our region, benefitting more than 40,000 pregnancies annually.
- Concentric under the Health Tech Adoption and Acceleration Fund (HTAFF), supporting OBO ICB: Impact assessment of induction of e-consulting software across Oxford University Hospitals NHS Foundation Trust and Buckinghamshire Healthcare NHS Trust.